Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Dogwood Therapeutics Inc DWTX

Healthcare Biotechnology
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced... see more

Current News (NDAQ:DWTX)

Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study

GlobeNewswire 2 days ago

Dogwood Therapeutics Announces First Quarter 2026 Financial Results

GlobeNewswire 6 days ago

Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026

GlobeNewswire 13 days ago

Dogwood Therapeutics Announces Worldwide Development and Commercialization Partnership for Anti-Viral Assets with Potential Value up to $100M

GlobeNewswire April 23, 2026

Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy

GlobeNewswire April 15, 2026

Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

GlobeNewswire March 18, 2026

Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026

GlobeNewswire February 2, 2026

Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development

GlobeNewswire January 12, 2026

Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain

GlobeNewswire December 22, 2025
View More News ››

Opinion & Analysis (NDAQ:DWTX)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:DWTX)

Using technical analysis for this stock.

It was time for me to be buying this one again,play it again Sam,right,so that my buy order for this one at $4.65 cents share mark was...
coolfooldumbguy - March 7, 2025

This stock is a big pump and a big dump

That's all it will be by the market manipulators out there.So that's pretty well all folks and good luck to all of you.
coolfooldumbguy - January 27, 2025

Sell buddy sell.Wow.

Otherwise you will be left holding the bag.Wow
coolfooldumbguy - January 27, 2025

biotech hot

take care in the volatility
thedave2006 - January 24, 2025

620% gain$

In and out of this one today!
Tradinghands - January 23, 2025

Sell buddy sell.Wow.

This one was flying today and it was a wonderful day for me to be day trading this stock.Well done because it was a big uptrend from the...
coolfooldumbguy - January 23, 2025
View more Bullboard ››

NurExone Biologic

NurExone Biologic

NurExone Biologic Inc., a pharmaceutical technology company, develops a platform for biologically guided exosome-based ...
View More »

Podcasts